Work

Phase II study evaluating olutasidenib and azacitidine in patients with IDH1 -mutated higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or advanced myeloproliferative neoplasms.

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps6586

Authors: Kelly Sharon Chien, Jeremy L. Ramdial, Wei Qiao, Rosmy John, Guillermo Montalban-Bravo, Nicholas James Short, Ghayas C. Issa, Farhad Ravandi-Kashani, Naval Guastad Daver, Tapan M. Kadia, Hagop M. Kantarjian, Guillermo Garcia-Manero, Courtney Denton Dinardo

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410814727

FWCI:

Cites:

Cited by:

Related to: 10